Trial Profile
Treatment-related deterioration of renal function as a biomarker to predict antitumour efficacy of sunitinib in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Aug 2015 New trial record